1.Fuzhou General Hospital of Nanjing Military Region��a. Department of Pharmacy��b. Department of Urology��Fuzhou 350025��China��2. School of Pharmacy��Shenyang Pharmaceutical University��Shenyang 110016��China��Fuzhou 350025��China
Abstract��
OBJECTIVE To investigate the effects of CYP3A5*3 and MDR1 G2677T/A on concentration/dosage*body surface area ratio (C/D��) and adverse effects of cyclosporine and acute rejection in renal transplant patients. METHODS The CYP3A5*3 and MDR1 G2677T/A genotypes of 141 renal transplant patients treated with cyclosporine were determined by PCR-RFLP method. The differences in C/D�� ratios, adverse reactions and acute rejection were compared among all of the genotype groups. RESULTS The C0/D�� ratios of CYP3A5*1/*1 and CYP3A5*1/*3 carriers were significantly lower than those of CYP3A5*3/*3 patients on 7th, 14th and 30th day after renal transplantation, while no significant difference was observed in adverse effects and acute rejection among different genotypes. The C/D�� ratios of three MDR1 G2677T/A genotypes showed significant difference on 7th, 14th and 30th day after renal transplantation except C2/D�� ratios on 14th day. The wild-type (G/G) had lower C/D�� ratios than mutant. The acute rejection incidenc showed significant difference among the three groups in three months without significant difference in adverse effects. CONCLUSIONCYP3A5*3 and MDR1 G2677T/A are correlated with C/D�� ratios in renal transplant patients, and the incidence of acute rejection in the three groups of MDR1 G2677T/A genotypes is significantly different. Clinical application of pharmacogenetic studies will be helpful for the individualization of cyclosporine dosage.
.Effects of CYP3A5*3 and MDR1 G2677T/A Genetic Polymorphism on Concentration and Efficacy of Cyclosporin in Renal Transplant Patients[J] Chinese Pharmaceutical Journal, 2011,V46(20): 1591-1596
��
[1]
TANABE M��IEIRI I��NAGATA N��et al. Expression of P-glycoprotein in human placenta�� Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene [J]. J Pharmacol Exp Ther��2001��297(3)��1137-1143. [2] TU X D��JIANG Q H��LAN F H. Comparison of three sample methods for genomic DNA extraction [J]. Chin J Lab Diagn(�й�ʵ�����ѧ)��2006��10(3)��264-266. [3] LOWN K S��MAYO R R��LECHTMAN A B��et al. Role of intestinal P-glycoprotein(mdr1) in interpatient variation in the oral bioavailability of cyclosporine[J]. Clin Pharmacol Ther��1997�� 62(3)��248-260. [4] KUEHL P��ZHANG J��LIN Y��et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet��2001��27(4)��383-391. [5] ROY J N��LAJOIE J��ZIJENAH L S��et al. CYP3A5 genetic polymorphisms in different ethnic populations[J]. Drug Metab Dispos��2005��33(7)��884-887. [6] ZHU B��CHEN G I��CHEN X P��et al. Genotype of CYP 3AP1 associated with CYP3A activity in Chinese Han population [J]. Acta Pharmacol Sin���й�ҩ��ѧ������2002��23(6)��567-572. [7] YATES C R��ZHANG W��SONG P��et al. The effect of CYP3A5 and MDR1polymorphic expression on cyclosporine oral disposition in renal transplant patients[J]. J Clin Pharmacol��2003��43(6)��555. [8] MAI I��PERLOFF E S��BAUER S��et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients[J]. Br J Clin Pharmacol��2004��58(5)��548-553. [9] SINGH R��KESARWANI P��SRIVASTAVA A��et al. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India[J]. Arch Med Res��2008��39(7)��695-701. [10] WANG Y��WANG C��LI J��et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem[J]. Eur J Clin Pharmacol��2009��65(3)��239-247. [11] QIU X Y��XIAO Z��ZHONG L J��et al. Influence of MDR1 genetic polymorphisms on ciclosporin pharmacokinetics in Chinese renal transplant patients[J]. Chin J Clin Pharm(�й��ٴ�ҩѧ��־)��2008��17(3)��141-147.
2011, Vol. 46 
